✦ LIBER ✦

Phosphorylated HER-2 tyrosine kinase and Her-2/neu gene amplification as predictive factors of response to trastuzumab in patients with HER-2 overexpressing metastatic breast cancer (MBC)

✍ Scribed by Rosa Giuliani; Virginie Durbecq; Angelo Di Leo; Marianne Paesmans; Denis Larsimont; Jean-Yves Leroy; Marleen Borms; Anita Vindevoghel; Guy Jerusalem; Veronique D’Hondt; Luc Dirix; Jean-Luc Canon; Vincent Richard; Veronique Cocquyt; Françoise Majois; Michel Reginster; Jan Demol; Jean-Pierre Kains; Paul Delree; Carine Keppens; Christos Sotiriou; Martine J. Piccart; Fatima Cardoso

Book ID: 116429234
Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 636 KB
Volume: 43
Category: Article
ISSN: 0959-8049
DOI: 10.1016/j.ejca.2006.11.019

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Predictive value of activated tyrosine k

Predictive value of activated tyrosine kinase (Tyr1248) in patients with HER2-overexpressing metastatic breast cancer (MBC) treated with trastuzumab + chemotherapy regimens

✍ R Giuliani; M Paesmans; V Durbecq; A Di Leo; D Larsimont; V Cocquyt; F Majois; C 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 329 KB

Tyrosine kinase activation in breast car

Tyrosine kinase activation in breast carcinoma with correlation to HER-2/neu gene amplification and receptor overexpression

✍ Rohit Bhargava; Rizwan Naeem; Sharon Marconi; Jason Luszcz; Jane Garb; Robert Ga 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 373 KB

Her-2/neu and EGFR tyrosine kinase activ

Her-2/neu and EGFR tyrosine kinase activation predict the efficacy of trastuzumab-based therapy in patients with metastatic breast cancer

✍ Gernot Hudelist; Wolfgang J. Köstler; Klaus Czerwenka; Ernst Kubista; Johannes A 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 French ⚖ 372 KB 👁 2 views

## Abstract Her‐2/__neu__ overexpression in human breast cancer leads to an aggressive biological behavior and poor prognosis. Although the anti‐Her‐2/__neu__ antibody trastuzumab (Herceptin®) has become a valuable therapeutic option for patients with Her‐2/__neu__‐overexpressing breast cancer, man

Phase II study of weekly docetaxel (Taxo

Phase II study of weekly docetaxel (Taxotere; txt) and trastuzumab (Herceptin; H) for patients with HER-2 overexpressing (HER2+) metastatic breast cancer (MBC)

✍ F.J. Esteva; V. Valero; D. Booser; L.T. Guerra; J.L. Murray; L. Pusztai; M. Cris 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 198 KB

Weekly Gemcitabine and Trastuzumab in th

Weekly Gemcitabine and Trastuzumab in the Treatment of Patients With HER2-Overexpressing Metastatic Breast Cancer

✍ Denise A. Yardley; Howard A. Burris III; Sarah Hanson; F. Anthony Greco; David R 📂 Article 📅 2009 🏛 CIG Media Group, LP. 🌐 English ⚖ 108 KB

Serum HER-2/neu and relative resistance

Serum HER-2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer

✍ Suhail M. Ali; Walter P. Carney; Francisco J. Esteva; Monica Fornier; Lyndsay Ha 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 175 KB 👁 2 views